Skip to content
Search our Site
Search our site
Search our site
About the EPDA
Political affairs and policy
Resources and publications
All research papers
Search research papers
Medication research papers
New treatments for the motor symptoms of Parkinson's disease
Authors provide an update since 2011 on new formulations of current drugs, new drugs with promising results in Phase II and Phase III clinical trials, old drugs with new possibilities and some new potential strategies that are currently in Phase I and II of development. Negative Phase II and Phase III clinical trials published since 2011 will also be briefly mentioned.
01 November 2014
Improving l-dopa therapy: The development of enzyme inhibitors
The introduction of levodopa produced a monumental change in the treatment of Parkinson's disease (PD). Limitations in its bioavailability and tolerability led to the search for drugs that could improve its pharmacokinetics and safety profile.
21 October 2014
Reports of Pathological Gambling, Hypersexuality, and Compulsive Shopping Associated With Dopamine Receptor Agonist Drugs
Findings confirm and extend the evidence that dopamine receptor agonist drugs are associated with these specific impulse control disorders. At present, none of the dopamine receptor agonist drugs approved by the FDA have boxed warnings as part of their prescribing information. Our data, and data from prior studies, show the need for more prominent warnings.
20 October 2014
Mind matters: placebo enhances reward learning in Parkinson's disease
Authors found that the mere expectation of dopamine release enhanced reward learning and modulated learning-related signals in the striatum and the ventromedial prefrontal cortex. These effects were selective to learning from reward: neither medication nor placebo had an effect on learning to avoid monetary loss.
19 October 2014
Dopaminergic agents and nutritional status in Parkinson's disease
Results: In linear regression, total levodopa (l-dopa) equivalent daily dose (LEDD) was associated with worse MNA (B = 0.14, 95% CI = 0.26-0.02; P = 0.019). This association remained significant only for l-dopa (B = 0.19, 95% CI = 0.32-0.52; P = 0.007), but not dopaminergic agent dosages. Increasing l-dopa dosages were associated with increasing probability of risk of malnutrition (P for trend = 0.049).
15 October 2014
Rotigotine vs ropinirole in advanced stage Parkinson's disease: A double-blind study
Conclusions: Rotigotine was well tolerated at doses up to 16 mg/24 h and showed similar efficacy to ropinirole except that the application site reaction was much higher in the rotigotine group.
13 October 2014
A Genetic Mouse Model of Parkinson's Disease Shows Involuntary Movements and Increased Postsynaptic Sensitivity to Apomorphine
Study results document for the first time a disturbance of ERK1/2 signaling regulation associated with apomorphine-induced involuntary movements in a genetic mouse model of synucleinopathy. This mouse model will be useful to identify novel therapeutic targets that can counteract abnormal dopamine-dependent striatal plasticity during both prodromal and manifest stages of PD.
12 October 2014
Safinamide for the treatment of Parkinson's disease
In this work authors examine the biochemical properties of synthetic and natural molecules that are capable of interfering on both DA system (via monoamine oxidase inhibition) and AS fibrillation.
10 October 2014
Norepinephrine Deficiency in Parkinson's Disease: The Case for Noradrenergic Enhancement
In addition to reducing the consequences of deficient noradrenergic signaling, enhancement strate gies have the potential for augmenting the effects of dopaminergic therapies in PD. Furthermore, early recognition of the various clinical manifestations associated with NE deficiency, which may precede development of motor symptoms, could provide a window of opportunity for neuroprotective interventions.
09 October 2014
Quantitative Proteomics Reveal a Feedforward Mechanism for Mitochondrial PARKIN Translocation and Ubiquitin Chain Synthesis
Study data reveal a feedforward mechanism that explains how PINK1 phosphorylation of both PARKIN and poly-UB chains synthesized by PARKIN drives a program of PARKIN recruitment and mitochondrial ubiquitylation in response to mitochondrial damage.
02 October 2014
Back to Top
Add page to PDF basket
Copyright © 2014 EPDA. All Rights Reserved.
Privacy and cookies